KRT5 and breast cancer: It has also been observed in luminal breast cancer cell lines (T47D and MCF7), which contain subpopulations of ER-/PR-/K5+ cells, that the K5+ cells are enriched for TIC activity and are resistant to conventional chemotherapies compared to ER+/PR+/K5- cells [56].